publication date: May. 4, 2018
NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase 1 – 10187
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
National Heart Lung and Blood Institute
Childs, Richard W.
Phase II – EA9171
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
Phase II – NRG-GU006
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
Feng, Felix Yi-Chung
Phase III – CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Canadian Cancer Trials Group
Whelan, Timothy Joseph
Phase Other – ANBL17B5-Q
Growth Factor Receptor Trafficking and Neuroblastoma Differentiation
Children’s Oncology Group
Zage, Peter Eric